Back to Search Start Over

The problem with potency

Authors :
Christopher Thomas Scott
Source :
Nature Biotechnology. 23:1037-1039
Publication Year :
2005
Publisher :
Springer Science and Business Media LLC, 2005.

Abstract

Industry hopes to build on recent successes of monoclonal antibodies in oncology and inflammatory disease. But evidence is mounting that the exquisite selectivity and binding capacity of these therapeutics can have unwanted side effects, particularly in autoimmune disease. Christopher Thomas Scott investigates.

Subjects

Subjects :
Autoimmune disease
medicine.drug_class
business.industry
fungi
Biomedical Engineering
Neoplasms therapy
Bioengineering
Monoclonal antibody
medicine.disease
Applied Microbiology and Biotechnology
Cytokines metabolism
Immunology
medicine
Molecular Medicine
Potency
business
Biotechnology

Details

ISSN :
15461696 and 10870156
Volume :
23
Database :
OpenAIRE
Journal :
Nature Biotechnology
Accession number :
edsair.doi...........f8ae897f7aa811da0cc1912b6a103648
Full Text :
https://doi.org/10.1038/nbt0905-1037
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details